Japan figures

Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan

https://www.cureus.com/articles/196275-increased-age-adjusted-cancer-mortality-after-the-third-mrna-lipid-nanoparticle-vaccine-dose-during-the-covid-19-pandemic-in-japan#!/

Gibo M, Kojima S, Fujisawa A, et al. (April 08, 2024) Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan. Cureus 16(4): e57860. DOI 10.7759/cureus.57860

Conclusions

Statistically significant increases in age-adjusted mortality rates of all cancer and some specific types of cancer, namely, ovarian cancer, leukemia, prostate, lip/oral/pharyngeal, pancreatic, and breast cancers, were observed in 2022 after two-thirds of the Japanese population had received the third or later dose of SARS-CoV-2 mRNA-LNP vaccine.

These particularly marked increases in mortality rates of these ERα-sensitive cancers may be attributable to several mechanisms of the mRNA-LNP vaccination,

rather than COVID-19 infection itself or reduced cancer care due to the lockdown.

Researchers have reported that the SARS-CoV-2 mRNA-LNP vaccine may pose the risk of development and progression of cancer.

Several case reports have described cancer developing or worsening after vaccination and discussed possible causal links between cancer and mRNA-LNP vaccination.

Details of the paper

No significant excess mortality was observed during the first year of the pandemic (2020).

However, some excess cancer mortalities were observed in 2021 after mass vaccination with the first and second vaccine doses,

and significant excess mortalities were observed for all cancers and some specific types of cancer after mass vaccination with the third dose in 2022.

During the COVID-19 pandemic

Excess deaths including cancer have become a concern in Japan

Study aimed to evaluate how age-adjusted mortality rates (AMRs) for different types of cancer in Japan changed during the COVID-19 pandemic (2020-2022).

Official statistics from Japan,

used to compare observed annual and monthly AMRs,

with predicted rates based on pre- pandemic (2010-2019) figures

In 2020

(first year of the pandemic)

Significant deficit mortality for all causes, and no excess mortality for all cancers.

In 2021

Significant excess mortality of 2.1% for all causes,

and 1.1% for all cancers.

In 2022

Excesses mortality, 9.6%

2.1% for all cancers